Scholarlink

Purpose <p>To compare the safety and clinical outcomes of genicular artery embolization (GAE) performed with permanent microspheres (PM) and imipenem/cilastatin (<i>I</i>/<i>C</i>) in patients with mild-to-moderate knee osteoarthritis.</p> Materials and Methods <p>In this IRB-approved prospective, randomized, single-center, single-blind trial, 60 patients with mild-to-moderate knee osteoarthritis were allocated to GAE with <i>I</i>/<i>C</i> (<i>n</i> = 30) or microspheres (<i>n</i> = 30). Clinical outcomes were assessed at baseline, 30&#xa0;days, 90&#xa0;days, and 365&#xa0;days using Visual Analog Scale (VAS), <i>Western Ontario and McMaster Universities Osteoarthritis Index</i> (WOMAC), and <i>Knee Injury and Osteoarthritis Outcome Score</i> (KOOS).</p> Results <p>Baseline characteristics were similar between groups, except for a higher rate of bilateral treatment in the microsphere group (56.6% vs. 30.0%, <i>p</i> = 0.037). Technical success was achieved in all procedures, with lower embolic volume in the microsphere group (<i>p</i> = 0.003). The mean volume of embolic was 1.5&#xa0;ml in the microsphere group and 2.0&#xa0;ml in the <i>I</i>/<i>C</i> group (<i>p</i> = 0.003). Between-group comparisons showed no significant differences in VAS at 30, 90, and 365&#xa0;days (3.20 vs. 2.28, <i>p</i> = 0.102; 3.38 vs. 3.33, <i>p</i> = 0.931; and 3.95 vs. 3.88, <i>p</i> = 0.928), in WOMAC pain (6.25 vs. 4.83, <i>p</i> = 0.182; 8.11 vs. 6.00, <i>p</i> = 0.051; and 7.50 vs 6.27, <i>p</i> = 0.323), or in KOOS pain (63.59 vs. 72.12, <i>p</i> = 0.115; 56.58 vs. 67.14, <i>p</i> = 0.074; and 53.76 vs. 65.81, <i>p</i> = 0.081) for <i>I</i>/<i>C</i> versus microspheres, respectively.</p> Conclusion <p>GAE using either <i>I</i>/<i>C</i> or microspheres is safe and effective, with significant clinical improvement over 12&#xa0;months and no major differences in adverse events and pain outcomes between embolic agents.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genicular Artery Embolization Using Imipenem/Cilastatin vs. Microsphere for Knee Osteoarthritis (GAUCHO). 12-Month Clinical Results of a Single-blind Randomized Controlled Trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月29日

查看全文
  • Mateus Picada Correa,
  • Alexandre Froes Michelin,
  • Lyson Azevedo Aguiar,
  • Ricardo Lugokenski,
  • Rodrigo Ilha Algarve,
  • Joaquim M. Motta-Leal-Filho

摘要

Purpose

To compare the safety and clinical outcomes of genicular artery embolization (GAE) performed with permanent microspheres (PM) and imipenem/cilastatin (I/C) in patients with mild-to-moderate knee osteoarthritis.

Materials and Methods

In this IRB-approved prospective, randomized, single-center, single-blind trial, 60 patients with mild-to-moderate knee osteoarthritis were allocated to GAE with I/C (n = 30) or microspheres (n = 30). Clinical outcomes were assessed at baseline, 30 days, 90 days, and 365 days using Visual Analog Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Knee Injury and Osteoarthritis Outcome Score (KOOS).

Results

Baseline characteristics were similar between groups, except for a higher rate of bilateral treatment in the microsphere group (56.6% vs. 30.0%, p = 0.037). Technical success was achieved in all procedures, with lower embolic volume in the microsphere group (p = 0.003). The mean volume of embolic was 1.5 ml in the microsphere group and 2.0 ml in the I/C group (p = 0.003). Between-group comparisons showed no significant differences in VAS at 30, 90, and 365 days (3.20 vs. 2.28, p = 0.102; 3.38 vs. 3.33, p = 0.931; and 3.95 vs. 3.88, p = 0.928), in WOMAC pain (6.25 vs. 4.83, p = 0.182; 8.11 vs. 6.00, p = 0.051; and 7.50 vs 6.27, p = 0.323), or in KOOS pain (63.59 vs. 72.12, p = 0.115; 56.58 vs. 67.14, p = 0.074; and 53.76 vs. 65.81, p = 0.081) for I/C versus microspheres, respectively.

Conclusion

GAE using either I/C or microspheres is safe and effective, with significant clinical improvement over 12 months and no major differences in adverse events and pain outcomes between embolic agents.